Press Releases Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Real-time Estimate Cboe Europe Other stock markets 03:35:29 06/05/2024 pm IST			5-day change	1st Jan Change
39.95 ^CHF	+0.13%		-0.75%	+13.03%

03/05	Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024	CI
09/04	Basilea Pharmaceutica Receives Grant for Antibiotics Program	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024	03/05	GL
Basilea shareholders approve all proposals of the board of directors at the annual general meeting	24/04	GL
Basilea shareholders approve all proposals of the board of directors at the annual general meeting	24/04	AQ
Actym Therapeutics Appoints Thomas Smart as CEO	24/04	PR
Basilea Pharmaceutica : Updated April 9, 2024	09/04	PU
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics	09/04	GL
Basilea Pharmaceutica : Updated April 4, 2024	04/04	PU
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications	04/04	GL
Basilea Pharmaceutica : Updated April 3, 2024	03/04	PU
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	11/03	GL
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	11/03	AQ
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	13/02	GL
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	13/02	DJ
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio	13/02	AQ
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea	19/01	GL
Cresemba(R) sales in Latin America trigger first sales milestone payment to Basilea	19/01	DJ
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea	19/01	AQ
Basilea announces acquisition of preclinical antibiotics program from Spexis	15/01	GL
Basilea announces acquisition of preclinical antibiotics program from Spexis	15/01	DJ
Basilea announces acquisition of preclinical antibiotics program from Spexis	15/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Press Releases

Filters